Sign up to save your podcasts
Or
Share A New Era in Urticaria Treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A New Era in Urticaria Treatment
In this episode of “All Things Urticaria” — a podcast from UCARE, the Global Allergy and Asthma Excellence Network — Prof. Torsten Zuberbier and Prof. Ana Giménez-Arnau discuss the newly released international urticaria guidelines. Developed with contributions from more than 100 societies and hundreds of experts worldwide, these guidelines represent a major step forward in the management of chronic spontaneous urticaria (CSU).
They discuss:
🔹 What makes the new urticaria guidelines more flexible than previous versions?
🔹 How has the treatment algorithm evolved beyond antihistamines and omalizumab?
🔹 What role do new therapies like remibrutinib and dupilumab play?
🔹 How can physicians choose the right treatment based on patient characteristics and comorbidities?
🔹 Why is early treatment escalation important for achieving disease control?
🔹 What does “assess and act” mean in daily clinical practice?
The episode highlights a shift toward individualized treatment decisions, shared decision-making with patients, and the integration of new therapeutic options. With a stronger focus on flexibility and real-world applicability, the new guidelines aim to improve outcomes for urticaria patients worldwide.
Key Learnings from the Episode:
The new urticaria guidelines are more flexible than previous versions.
Treatment decisions can now be individualized based on patient needs.
New therapies such as remibrutinib and dupilumab expand treatment options.
Omalizumab remains an important and well-established therapy.
Early escalation of treatment is key when antihistamines fail.
Combination therapies are now possible in certain cases.
Comorbidities should guide treatment choice.
Patient-reported outcomes are essential for disease management.
Tools like the CRUSE app support monitoring and decision-making.
“Assess and act” is a central principle in modern urticaria care.
Chapters:
00:00 Introduction to New Guidelines on Urticaria
03:35 Flexibility in Treatment Options
06:21 Understanding Non-Response and Treatment Decisions
09:08 Choosing the Right Treatment for Urticaria
12:00 Patient-Centered Care and Communication
14:37 Conclusion and Future Directions
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Feedback form: ATU: https://forms.office.com/e/m6a2uEdsUH
View all episodes
By UCARE, the Global Allergy and Asthma Excellence Network for UrticariaIn this episode of “All Things Urticaria” — a podcast from UCARE, the Global Allergy and Asthma Excellence Network — Prof. Torsten Zuberbier and Prof. Ana Giménez-Arnau discuss the newly released international urticaria guidelines. Developed with contributions from more than 100 societies and hundreds of experts worldwide, these guidelines represent a major step forward in the management of chronic spontaneous urticaria (CSU).
They discuss:
🔹 What makes the new urticaria guidelines more flexible than previous versions?
🔹 How has the treatment algorithm evolved beyond antihistamines and omalizumab?
🔹 What role do new therapies like remibrutinib and dupilumab play?
🔹 How can physicians choose the right treatment based on patient characteristics and comorbidities?
🔹 Why is early treatment escalation important for achieving disease control?
🔹 What does “assess and act” mean in daily clinical practice?
The episode highlights a shift toward individualized treatment decisions, shared decision-making with patients, and the integration of new therapeutic options. With a stronger focus on flexibility and real-world applicability, the new guidelines aim to improve outcomes for urticaria patients worldwide.
Key Learnings from the Episode:
The new urticaria guidelines are more flexible than previous versions.
Treatment decisions can now be individualized based on patient needs.
New therapies such as remibrutinib and dupilumab expand treatment options.
Omalizumab remains an important and well-established therapy.
Early escalation of treatment is key when antihistamines fail.
Combination therapies are now possible in certain cases.
Comorbidities should guide treatment choice.
Patient-reported outcomes are essential for disease management.
Tools like the CRUSE app support monitoring and decision-making.
“Assess and act” is a central principle in modern urticaria care.
Chapters:
00:00 Introduction to New Guidelines on Urticaria
03:35 Flexibility in Treatment Options
06:21 Understanding Non-Response and Treatment Decisions
09:08 Choosing the Right Treatment for Urticaria
12:00 Patient-Centered Care and Communication
14:37 Conclusion and Future Directions
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
Feedback form: ATU: https://forms.office.com/e/m6a2uEdsUH